We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A Better Way to Deliver Dendritic Cell Vaccines

By Biotechdaily staff writers
Posted on 20 May 2002
An animal study has shown that a new method of delivering dendritic cell vaccines is much faster and less expensive than the conventional method. Conducted by scientists at the University of Texas Southwestern Medical Center (UT, Dallas, USA), the study was published in the December 28, 2002, issue of Nature Biotechnology.

Dendritic cells signal T lymphocytes to multiply and initiate an immune response against bacteria, viruses, and cancer cells and are thus good vaccine candidates. However, the conventional method of culturing cells in a petri dish is a time-consuming, expensive process that has deterred broad vaccine application. Now, a new procedure developed and tested in mice enables researchers to manipulate dendritic cells in the skin instead of a petri dish and reduces the time required from 10 days to 24 hours.

Here is how the new delivery method works. Upon exposure to the chemical hapten, immature dendritic cells in the epidermis known as Langerhans cells mature and migrate to draining lymph nodes. A key chemokine (MIP3beta) helps to attract the migrating cells and mediate the migration process. The researchers created an artificial trap for Langerhans cells by implanting a polymer rod under the skin that was synthesized with ethylene-vinyl-acetate to release this chemokine. After the rod was implanted, hapten was applied to trigger the Langerhans cell migration. The cells homed in to the lymph nodes and created an accumulation of Langerhans cells around the rod.

In a second experiment, the researchers utilized a polymer rod releasing a tumor-associated antigen that was implanted under the skin, believing that the Langerhans cells would carry the antigen to the draining lymph nodes and initiate immunity against tumor development. Subsequent experiments with different tumor models have demonstrated that this strategy is efficacious.

"We believe that our in situ Langerhans cell vaccine format represents a breakthrough in the tumor vaccines field, thus moving it toward practical medicine,” said Dr. Akira Takashima, professor of dermatology at UT Southwestern.




Related Links:
University of Texas Southwestern Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Manual Pipetting Aid
Pipette Controllers macro
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
20 May 2002  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
20 May 2002  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
20 May 2002  |   BioResearch